

Supplementary Appendix 5: Relative ratios, seroconversion and proportion of patients attaining the median convalescent serum level for SARS-CoV-2 after BNT162b2 or mRNA-1273 vaccination excluding patients with prior COVID-19 or anti-nucleocapsid seroconversion

Weeks after second dose	Antibody	Relative ratio, median (IQR)*		No. (%) of patients with seroconversion†		No. (%) of patients who reached convalescent level‡	
		BNT162b2	mRNA-1273	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273
6-7	Anti-spike	1.57 (1.17-1.67)	1.72 (1.68-1.79)	55 (96) n=57	73 (96) n=76	38 (67) n=57	72 (95) n=76
	Anti-RBD	1.09 (0.48-1.50)	1.42 (1.29-1.52)	49 (86) n=57	73 (96) n=76	26 (46) n=57	59 (78) n=76
	Anti-NP	-	-	0 (0) n=57	0 (0) n=76	0 (0) n=57	0 (0) n=76
12	Anti-spike	1.42 (1.01-1.58)	1.93 (1.76-2.01)	103 (95) n=108	62 (95) n=65	58 (54) n=108	62 (95) n=65
	Anti-RBD	0.84 (0.33-1.35)	1.30 (1.04-1.43)	93 (86) n=108	61 (94) n=65	37 (34) n=108	39 (60) n=65
	Anti-NP	-	-	0 (0) n=108	0 (0) n=65	0 (0) n=108	0 (0) n=65

Note: IQR=interquartile range, NP=nucleocapsid protein, RBD=receptor binding domain.

Note: Patients were excluded if they had a positive RT-PCR for SARS-CoV-2 or anti-NP seroconversion at any point

* Summary statistics are not reported for anti-NP as it used as a binary measure of natural SARS-CoV-2 infection.

†Antibody levels are reported as relative ratios to synthetic standards. Seroconversion threshold level represents a positive test and are 0.19, 0.186, and 0.396 for anti-spike, anti-RBD, anti-NP antibodies, respectively.

Appendix 5, as supplied by the authors. Appendix to: Yau K, Chan CT, Abe KT, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. *CMAJ* 2022. doi: 10.1503/cmaj.211881. Copyright © 2022 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.

‡ The median level of antigen in convalescent serum is from a cohort of 211 patients in the general population with prior COVID-19 of all severities represents a robust antibody response: 1.38, 1.25, and 1.13 for anti-spike, anti-RBD, and anti-NP antibodies respectively.